Lexaria Bioscience (LLX.C) announced today that treatment and dosing in its human clinical study, HYPER-H21-1, have been completed ahead of schedule. Read full article here: https://equity.guru/2021/06/07/lexaria-bioscience-lxx-c-releases-progress-report-for-first-human-clinical-study/…
LXX.C
Lexaria Bioscience (LLX.C) announced today that treatment and dosing in its human clinical study, HYPER-H21-1, have been completed ahead of schedule. “Completing this work in the midst of…
Lexaria Bioscience (LXX.C) has received test results for two new DehydraTECH 2.0 cannabidiol (CBD) formulations in its second 2021 applied research and development study program, HYPER-A21-2. Read full article…
Lexaria Bioscience (LXX.C) has received test results for two new DehydraTECH 2.0 cannabidiol (CBD) formulations in its second 2021 applied research and development study program, HYPER-A21-2. “One of our…
Lexaria Bioscience (LXX.C) has provided positive results from its extended stability testing, which has reported unparalleled stability for bottled cannabidiol (CBD)-containing beverages prepared using its technology. “I love reminding…
Earlier this week, a subsidiary of Lexaria Bioscience (LXX.C) received a R&D license from Health Canada, prompting the question, ‘we have those?’ “You were as surprised as we were,” said…